Is Alpa Laboratorie overvalued or undervalued?

As of 29 May 2025, Alpa Laboratorie has moved from a fair to a very attractive valuation grade. The company is currently considered undervalued, with a price-to-earnings (PE) ratio of 10.70, a price-to-book value of 1.22, and an EV to EBITDA ratio of 20.22. These metrics indicate that Alpa Laboratorie is trading at a significant discount compared to its peers, particularly when compared to Sun Pharma, which has a PE ratio of 35.25, and Divi's Lab, which stands at a staggering 79.33. In terms of performance, Alpa Laboratorie's return on equity (ROE) is 11.42%, which is competitive within the industry. The PEG ratio of 0.65 further highlights its growth potential relative to its valuation. While the stock has underperformed the Sensex in the short term, it has shown impressive long-term gains, with a five-year return of 394.42%, significantly outpacing the Sensex's 143.05%. Overall, Alpa Laboratorie presents a compelling investment opportunity given its attractive valuation metrics and growth prospects.